

APPENDIX A

1. A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting essentially of: first molecules directed against CD3, and second molecules, distinct from said first molecules, said second molecules directed against CD7, wherein at least one of said first and said second molecules include a toxic moiety.
2. The method according to claim 15, wherein said second molecules specifically recognize CD7.
3. The pharmaceutical composition of claim 1, wherein said first molecules are antibodies.
4. The pharmaceutical composition of claim 1, wherein said second molecules are antibodies.
5. The pharmaceutical composition of claim 1, wherein said toxic moiety is ricin.
6. The pharmaceutical composition of claim 5, wherein said ricin is deglycosylated ricin A.
7. The pharmaceutical composition of claim 1, wherein said toxic moiety is chemically linked to said first and/or second molecules.
8. The pharmaceutical composition of claim 1, wherein said first and second molecules are provided with toxic moieties, which may be the same or different toxic moieties.
10. The pharmaceutical composition of claim 1, wherein said first molecules are gamma2B IgG.
11. The pharmaceutical composition of claim 5, wherein the toxic moiety is at least the equivalent dose of 25 micrograms of ricin A per square meter of body surface of a subject to which the composition is to be administered.
12. The pharmaceutical composition of claim 11, wherein the toxic moiety is at least the equivalent dose of 100 micrograms of ricin A per square meter of the subject's body surface per administration.
13. The pharmaceutical composition of claim 11, wherein the toxic moiety is at most the equivalent dose of 25 mg of ricin A per square meter of the subject's body surface per infusion.
15. A method of treating a disease state in a subject believed to be suffering therefrom, said disease state comprising at least one of Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune disease, said method comprising administering to the subject an amount of a pharmaceutical composition consisting essentially of: first molecules directed against a CD3


positive cell, and second molecules, distinct from said first molecules, directed against a CD7 positive cell, wherein at least the second molecules include a toxic moiety.

18. The pharmaceutical composition of claim 2, wherein said first molecules are antibodies.
19. The pharmaceutical composition of claim 18, wherein said second molecules are antibodies.
20. The pharmaceutical composition of claim 19, wherein said toxic moiety is deglycosylated ricin A.
21. The pharmaceutical composition of claim 19, wherein said toxic moiety is chemically linked to said first and second molecules.
22. The pharmaceutical composition of claim 21, wherein both said first and second molecules are provided with toxic moieties, which may be the same or different toxic moieties.
23. The pharmaceutical composition of claim 18, wherein said first molecules are gamma2B IgG.
24. A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting essentially of: anti-CD3 antibodies; and anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.
25. A method of treating a disease state in a subject believed to be suffering therefrom, said disease state comprising at least one of Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune diseases, said method comprising administering to the subject an amount of a pharmaceutical composition consisting essentially of: anti-CD3 antibodies; and anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.
26. The composition of claim 1, wherein said second molecules include a toxic moiety.

THE PATENT & TRADEMARK OFFICE MAILROOM DATE
STAMPED HEREON IS AN ACKNOWLEDGEMENT THAT ON THIS
DATE THE PATENT & TRADEMARK OFFICE RECEIVED:

Brief on Appeal (16 pages); Petition for Extension of Time (1 page);
Check no. 5606 in the amount of \$210.00

Invention: METHODS AND MEANS FOR THE TREATMENT
OF IMMUNE RELATED DISEASES
Applicant(s): van Oosterhout et al.
Filing Date: September 22, 2000
Serial No.: 09/668,555
Date Sent: January 14, 2004 via Express Mail Label No.
EL994821789US
Docket No.: 2183-4541US
ACT/add



RECEIVED
JAN 26 2004
TRASKBRITT, P.C.



TRASKBRITT
P.O. Box 2550
Salt Lake City, UT 84110-2550



WARNING: THIS DOCUMENT HAS FLUORESCENT FIBERS.

VOID PANTOGRAPH AND A MICROPRINT SIGNATURE LINE

TRASK BRITT, P.C.

PATENT ATTORNEYS' CLIENT ADVANCE ACCOUNT

230 SOUTH 500 EAST, SUITE 300

P.O. BOX 2550

SALT LAKE CITY, UT 84102

PHONE: 801-532-1922

KEY BANK OF UTAH
SALT LAKE CITY, UT


31-75 / 1240

5601

DATE 01/14/2004

PAY
EXACTLY Two Hundred Ten AND 00/100 DOLLARS

\$ 210.00

TO THE
ORDER OFCommissioner for Patents
Washington, D.C. 20231

AUTHORIZED SIGNATURE

⑈005606⑈ ⑆124000737⑆445010010416⑈

⑈00000021000⑈



EL 994821789 US

Mailing Label
Label T-F June 2002

Post Office To Addressee

ORIGIN (POSTAL USE ONLY)				DELIVERY (POSTAL USE ONLY)			
PO ZIP Code	Day of Delivery <input type="checkbox"/> Next <input type="checkbox"/> Second	Flat Rate Envelope		Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature	
Date In Mo. Day Year	<input type="checkbox"/> 1st Noon <input type="checkbox"/> 3 PM	Postage		Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature	
Time In <input type="checkbox"/> AM <input type="checkbox"/> PM	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Return Receipt Fee		Delivery Date	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature	
Weight lbs. ozs.	Int'l Alpha Country Code	COD Fee	Insurance Fee	<input type="checkbox"/> WARNING OF SIGNATURE REQUIRED On delivery, the addressee must sign for the item. If the addressee is not available, the delivery employee must obtain a signature from someone at the address or the addressee's agent. If the addressee is not available, the delivery employee must obtain a signature from someone at the address or the addressee's agent. If the addressee is not available, the delivery employee must obtain a signature from someone at the address or the addressee's agent.			
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Acceptance Clerk Initials	Total Postage & Fees		<input type="checkbox"/> NO DELIVERY <input type="checkbox"/> Resend <input type="checkbox"/> Hold			
CUSTOMER USE ONLY METHOD OF PAYMENT: Express NM Corporate Acct. No. X841812				Federal Agency Acct. No. or Postal Service Acct. No.			
FROM: (PLEASE PRINT) PHONE 801 532 1922 TRASK BRITT LAW OFFICE 230 S 500 E STE 300 SALT LAKE CITY UT 84102-2000				TO: (PLEASE PRINT) PHONE MAIL STOP APPEAL BRIEF - PATENTS COMMISSIONER FOR PATENTS US PATENTS OFFICE PO BOX 1450 ALEXANDRIA VA 22313-1450			
PRESS HARD. You are making 3 copies. FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com							

THE PATENT & TRADEMARK OFFICE MAILROOM DATE
STAMPED HEREON IS AN ACKNOWLEDGEMENT THAT ON THIS
DATE THE PATENT & TRADEMARK OFFICE RECEIVED:

Brief on Appeal (16 pages); Petition for Extension of Time (1 page);
Check no. 5606 in the amount of \$210.00

Invention: METHODS AND MEANS FOR THE TREATMENT
OF IMMUNE RELATED DISEASES
Applicant(s): van Oosterhout et al.
Filing Date: September 22, 2000
Serial No.: 09/668,555
Date Sent: January 14, 2004 via Express Mail Label No.
EL994821789US
Docket No.: 2183-4541 US
ACT/sdd

560

TRASK BRITT, P.C. PATENT ATTORNEYS / CLIENT ADVANCE ACCOUNT

SD

DATE	INVOICE #	REFERENCE	AMOUNT
01/14/2004		Extension for Response within Second Mon 2183-4541US	210.00

210.00

WARNING THIS DOCUMENT HAS FLUORESCENT FIBERS, A VOID PANTOGRAPH AND A MICROPRINT SIGNATURE LINE

TRASK BRITT, P.C.
PATENT ATTORNEYS / CLIENT ADVANCE ACCOUNT
230 SOUTH 500 EAST, SUITE 300
P.O. BOX 2550
SALT LAKE CITY, UT 84102
PHONE: 801-532-1922

KEY BANK OF UTAH
SALT LAKE CITY, UT


03-73 / 1240

DATE 01/14/2004

PAY
EXACTLY Two Hundred Ten AND 00/100 DOLLARS

\$ 210.00

TO THE
ORDER OF Commissioner for Patents
Washington, D.C. 20231



AUTHORIZED SIGNATURE

⑈005606⑈ ⑆124000717⑆445010030416⑈